Latest news with #PES
Yahoo
20-05-2025
- Health
- Yahoo
Soleno Therapeutics Announces Data Presentation Showing that Resumption of Treatment with VYKAT(TM) XR after a Randomized Withdrawal Period was Associated with Significant Improvements in Hyperphagia and Behavioral Symptoms in Participants with Prader-Willi Syndrome
REDWOOD CITY, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced data presented from its clinical development program of VYKAT™ XR (diazoxide choline) extended-release tablets, previously referred to as DCCR, at the Pediatric Endocrine Society (PES) Annual Meeting 2025, which was held May 15-18 in National Harbor, Maryland, USA. The presentation showed that resumption of VYKAT XR treatment in participants with PWS following a 16-week randomized withdrawal was associated with significant improvements in both hyperphagia and behavioral symptoms. 'We are pleased to share the results from our ongoing clinical development program for VYKAT XR,' said Anish Bhatnagar, M.D., Chairman and Chief Executive Officer of Soleno Therapeutics. 'These results support the effectiveness of VYKAT XR in managing the critical symptoms of PWS and highlight the importance of long-term, continuous treatment.' Data Presented at the 2025 Pediatric Endocrine Society (PES) Annual Meeting Following long-term open label treatment with VYKAT XR for approximately 3 years (C602-OLE) and 16 weeks of randomized withdrawal (C602-RWP), participants who were randomized to placebo and restarted VYKAT XR in the open-label Study C614 showed improvements in hyperphagia by 13 weeks, with continued benefit through one year. Specifically, these participants showed a 6.3-point reduction in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) total score at one year —returning to levels similar to their pre-withdrawal baseline. Behavioral improvements were also demonstrated through one year, with improvements across all six domains assessed. About PWSThe Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The hallmark symptom of this disorder is hyperphagia, a chronic and life-threatening condition characterized by feelings of intense, persistent hunger, food pre-occupation, and an extreme drive to seek and consume food, which can severely diminish the quality of life for individuals with PWS and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease. About VYKAT XR VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients. VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). IMPORTANT SAFETY INFORMATION ContraindicationsUse of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides. Warnings and Precautions HyperglycemiaHyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia. Risk of Fluid OverloadEdema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients. Adverse ReactionsThe most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash. Please see the full Prescribing Information, including Medication Guide. About Soleno Therapeutics, is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome. For more information, please visit Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those described in the company's prior press releases and in the periodic reports it files with the SEC. The events and circumstances reflected in the company's forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Corporate Contact:Brian RitchieLifeSci Advisors, LLC212-915-2578 Media Contact:Soleno Therapeuticsmedia@ #2Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time of India
10-05-2025
- General
- Time of India
Meghalaya embraces Miyawaki method for promoting afforestation
1 2 Shillong: Meghalaya is taking a step forward in protecting the environment by using the Miyawaki Forest method — a fast and effective way of growing dense, native forests .This method was developed in Japan by botanist Akira Miyawaki and is now being used across the state as part of an afforestation project led by the state soil and water conservation Conrad K Sangma played a key role in pushing for environmental conservation and raised serious concerns about deforestation across the state and has been working to restore green cover through various programmes."To support this effort, the state has initiated different interventions including 'Green Meghalaya' and has partnered with different organisations to promote conservation and afforestation programme. The state govt is also providing financial incentives through the Payment for Ecosystem Services (PES) for conservation of forest cover," an official statement Thursday, the CM visited a Miyawaki forest site at Mawsharoh, Ummir, in East Khasi Hills district, where the method is being used to grow a forest on a 1.5-hectare area. Operation Sindoor Pak drones enter Indian airspace, explosions heard just hours after truce deal Sirens, explosions in border districts after Pak breaks deal: What we know so far 'What happened to ceasefire?' J&K CM after explosions heard across Srinagar Currently, similar projects are being implemented on a total of 25,000 hectares throughout from the soil and water conservation department shared how the Miyawaki method is helping to restore the ecosystem. "The method involves planting native trees close together in layers, which leads to rapid growth of dense, self-sustaining forests. These forests grow faster than traditional plantations and require less maintenance over time," the official statement project is being carried out with strong support from local communities, who are actively involved in the planting and caring of these forests. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Click Here - This Might Save You From Losing Money Expertinspector Click Here Undo The first Miyawaki forest plantation in Meghalaya began three years ago in Garo Hills as a pilot project."The project will be expanded across the state as one of our main afforestation drives," the CM said."The Miyawaki method not only helps restore greenery but also brings many other benefits. These mini-forests help absorb carbon dioxide, fight climate change, improve air quality, reduce noise pollution, and provide shelter for wildlife. Meghalaya's rich soil and unique climate make it ideal for growing these forests," the official statement said.
New Indian Express
05-05-2025
- Politics
- New Indian Express
Why the Census isn't an answer to all questions
The Union government has announced that caste enumeration would be a part of the next nationwide census. Population enumeration by castes has not been published after 1931. The reason being that caste was a colonial invention that tried to replace varna and jati, and later amended with ethnographic surveys, occupation and social hierarchies. This attempt made caste a fluid identity, making it inconvenient to fit into the diverse social systems in India. However, caste debates based on the censuses from 1881 to 1931 continue till today. A list of castes can be enforced by law, while social identities continue to be more varied—the consequent problems should be tackled. Another real problem may crop up about estimating the socio-economic characteristics of each caste to design reservation policies and deliver welfare schemes. This can be captured only when a full-fledged census that includes a large number of socio-economic variables and caste information is conducted under the purview of the Census Act. Even after enumeration, a better validation of the census data is always required, as it is also prone to errors. It is to be noted that the net omission rate, measured as the ratio of the number of omitted persons per 1,000 persons enumerated in the census after adjusting for duplication, was nearly 20 percent on average in the last four decennial exercises. A general practice of a census operation is that it is followed by a Post-Enumeration Survey (PES), which involves carrying out an independent survey for a sample of the population to ascertain the accuracy of the information. The PES helps in identifying under-enumeration or over-enumeration across coverage areas. India has conducted a PES after every decennial census, but has not published the data gathered or the error corrections. This only increases our apprehension about the quality of enumeration and estimation from the census.
Business Wire
03-05-2025
- Business
- Business Wire
AdvanSix Announces First Quarter 2025 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--AdvanSix (NYSE: ASIX), a diversified chemistry company, today announced its financial results for the first quarter ending March 31, 2025. Overall, year-over-year results reflect improved operational performance, continued strength in Plant Nutrients, and the previously announced insurance settlement proceeds. First Quarter 2025 Summary Sales up approximately 12% versus prior year driven by an approximately 7% increase in volume, 4% favorable market-based pricing and 1% higher raw material pass-through pricing Net Income of $23.3 million, an increase of $40.7 million versus the prior year Adjusted EBITDA of $51.6 million, an increase of $51.0 million versus the prior year Adjusted EBITDA Margin of 13.7%, up 1,350 bps versus the prior year Cash Flow from Operations of $11.4 million, an increase of $47.6 million versus the prior year Capital Expenditures of $34.1 million, a decrease of $1.3 million versus the prior year Free Cash Flow of ($22.6) million, an increase of $49.0 million versus the prior year "Our significantly improved first quarter results demonstrate our commitment to execute in an evolving macroeconomic environment as we delivered operational performance to meet our customers' needs and drove the successful conclusion of our multi-year efforts to recover losses associated with the 2019 PES cumene supplier shutdown,' said Erin Kane, president and CEO of AdvanSix. 'Our competitive position enabled our commercial team to achieve a 4% increase in market pricing led by strength in Plant Nutrients with continued robust ammonium sulfate premiums over urea, while we navigated margin impact driven by higher raw material prices, namely natural gas and sulfur. We remain well positioned to serve our customers across our diversified portfolio including fertilizer as the domestic planting season progresses, in acetone amid a balanced global supply and demand environment, and across a modestly recovering nylon industry. We have supplemented our commercial success with continued investment in growth and enterprise initiatives in support of sustainably improving through-cycle performance." Summary first quarter 2025 financial results for the Company are included below: Sales of $378 million in the quarter increased approximately 12% versus the prior year. Sales volume increased approximately 7% primarily driven by improved performance following the operational disruption in the prior year period and higher granular ammonium sulfate sales supported by our SUSTAIN program. Market-based pricing was favorable by 4% driven by continued strength in Plant Nutrients reflecting favorable North American ammonium sulfate supply and demand conditions. Raw material pass-through pricing was up 1%. Sales by product line and approximate percentage of total sales are included below: Adjusted EBITDA of $51.6 million in the quarter increased $51.0 million versus the prior year primarily driven by improved operational performance, higher volume, and $26 million of insurance proceeds, partially offset by unfavorable net pricing over raw materials. Adjusted earnings per share of $0.93 increased $1.49 versus the prior year driven primarily by the factors discussed above. Cash flow from operations of $11.4 million in the quarter increased $47.6 million versus the prior year primarily due to higher net income. Capital expenditures of $34.1 million in the quarter decreased $1.3 million versus the prior year. Outlook Strong sulfur nutrition demand and tight North American ammonium sulfate supply expected to support sulfur premiums at or near high end of historical range; Anticipated higher raw material prices impacting fertilizer margins Acetone spread over refinery grade propylene costs anticipated to be lower year-over-year, in part due to higher input costs, but expected to remain at or above cycle averages Leveraging our nylon competitive position to navigate a more protracted downturn in the cycle - global oversupply conditions impacting industry pricing dynamics Expect Capital Expenditures of $145 to $155 million in 2025, reflecting the planned progression of our SUSTAIN growth program, and refined execution timing to address critical enterprise risk mitigation Continue to expect pre-tax income impact of plant turnarounds to be $25 to $30 million in 2025 versus approximately $58 million in 2024 "While we know that 2025 will again be another dynamic year, we are well-positioned as an American manufacturer of essential chemistries aligned to domestic agricultural and manufacturing supply chains and energy markets as well as a diverse set of end market applications, and will continue to pivot where needed. In times of uncertainty, we're keenly focused on delivering on what we can control. This includes taking a measured and disciplined approach to cost and cash management while maintaining smart investments for sustainable long-term performance. We also continue to protect our healthy balance sheet enabling our strategic capital allocation framework to provide optionality for further value creation and remain confident in the potential of AdvanSix,' concluded Kane. Dividend The Company's Board of Directors declared a quarterly cash dividend of $0.16 per share on the Company's common stock. The dividend is payable on May 27, 2025 to stockholders of record as of the close of business on May 13, 2025. Conference Call Information AdvanSix will discuss its results during its investor conference call today starting at 9:30 a.m. ET. To participate on the conference call, dial (844) 855-9494 (domestic) or (412) 858-4602 (international) approximately 10 minutes before the 9:30 a.m. ET start, and tell the operator that you are dialing in for AdvanSix's first quarter 2025 earnings call. The live webcast of the investor call as well as related presentation materials can be accessed at Investors can hear a replay of the conference call from 12 noon ET on May 2 until 12 noon ET on May 9 by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international). The access code is 5103628. About AdvanSix AdvanSix is a diversified chemistry company that produces essential materials for our customers in a wide variety of end markets and applications that touch people's lives. Our integrated value chain of our five U.S.-based manufacturing facilities plays a critical role in global supply chains and enables us to innovate and deliver essential products for our customers across building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, electronics and other end markets. Guided by our core values of Safety, Integrity, Accountability and Respect, AdvanSix strives to deliver best-in-class customer experiences and differentiated products in the industries of nylon solutions, plant nutrients, and chemical intermediates. More information on AdvanSix can be found at Forward Looking Statements This release contains certain statements that may be deemed 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, that address activities, events or developments that our management intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements may be identified by words such as "expect," "anticipate," "estimate," 'outlook,' "project," "strategy," "intend," "plan," "target," "goal," "may," "will," "should" and "believe" and other variations or similar terminology and expressions. Although we believe forward-looking statements are based upon reasonable assumptions, such statements involve known and unknown risks, uncertainties and other factors, many of which are beyond our control and difficult to predict, which may cause the actual results or performance of the Company to be materially different from any future results or performance expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: general economic and financial conditions in the U.S. and globally; the potential effects of inflationary pressures, tariffs or the imposition of new tariffs, trade wars, barriers or restrictions, or threats of such actions, changes in interest rates, labor market shortages and supply chain issues; instability or volatility in financial markets or other unfavorable economic or business conditions caused by geopolitical concerns, including as a result of new or proposed regulatory, trade or other policies of the U.S., and the conflict between Russia and Ukraine, the conflict in Israel and Gaza and related uncertainty in the surrounding region, and the possible expansion of such conflicts; the effect of any of the foregoing on our customers' demand for our products and our suppliers' ability to manufacture and deliver our raw materials, including implications of reduced refinery utilization in the U.S.; our ability to sell and provide our goods and services; the ability of our customers to pay for our products; any closures of our and our customers' offices and facilities; risks associated with increased phishing, compromised business emails and other cybersecurity attacks, data privacy incidents and disruptions to our technology infrastructure; risks associated with operating with a reduced workforce; risks associated with our indebtedness including compliance with financial and restrictive covenants, and our ability to access capital on reasonable terms, at a reasonable cost, or at all, due to economic conditions or otherwise; the impact of scheduled turnarounds and significant unplanned downtime and interruptions of production or logistics operations as a result of mechanical issues or other unanticipated events such as fires, severe weather conditions, natural disasters, pandemics and geopolitical conflicts and related events; price fluctuations, cost increases and supply of raw materials; our operations and growth projects requiring substantial capital; growth rates and cyclicality of the industries we serve including global changes in supply and demand; failure to develop and commercialize new products or technologies; loss of significant customer relationships; adverse trade and tax policies; extensive environmental, health and safety laws that apply to our operations; hazards associated with chemical manufacturing, storage and transportation; litigation associated with chemical manufacturing and our business operations generally; inability to acquire and integrate businesses, assets, products or technologies; protection of our intellectual property and proprietary information; prolonged work stoppages as a result of labor difficulties or otherwise; failure to maintain effective internal controls; our ability to declare and pay quarterly cash dividends and the amounts and timing of any future dividends; our ability to repurchase our common stock and the amount and timing of any future repurchases; disruptions in supply chain, transportation and logistics; potential for uncertainty regarding qualification for tax treatment of our spin-off; fluctuations in our stock price; and changes in laws or regulations applicable to our business. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Such forward-looking statements are not guarantees of future performance, and actual results, developments and business decisions may differ materially from those contemplated by such forward-looking statements as a result of a number of risks, uncertainties and other factors including those noted above and those identified in our filings with the Securities and Exchange Commission (SEC), including the risk factors in Part 1, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, as updated in subsequent reports filed with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on our behalf are qualified in their entirety by this paragraph. We do not undertake to update or revise any of our forward-looking statements. Non-GAAP Financial Measures This press release includes certain non-GAAP financial measures intended to supplement, not to act as substitutes for, comparable GAAP measures. Reconciliations of non-GAAP financial measures to GAAP financial measures are provided in this press release. Investors are urged to consider carefully the comparable GAAP measures and the reconciliations to those measures provided. Non-GAAP measures in this press release may be calculated in a way that is not comparable to similarly-titled measures reported by other companies. March 31, 2025 ASSETS Current assets: Cash and cash equivalents $ 8,344 $ 19,564 Accounts and other receivables – net 179,336 145,673 Inventories – net 222,857 212,386 Taxes receivable 55 503 Other current assets 7,590 8,990 Total current assets 418,182 387,116 Property, plant and equipment – net 926,006 917,858 Operating lease right-of-use assets 144,844 153,438 Goodwill 56,192 56,192 Intangible assets 42,382 43,144 Other assets 38,368 37,172 Total assets $ 1,625,974 $ 1,594,920 LIABILITIES Current liabilities: Accounts payable $ 238,906 $ 228,761 Accrued liabilities 42,775 47,264 Income taxes payable 2,590 1,047 Operating lease liabilities – short-term 40,093 42,493 Deferred income and customer advances 26,582 37,538 Total current liabilities 350,946 357,103 Deferred income taxes 149,346 145,299 Operating lease liabilities – long-term 105,437 111,400 Line of credit – long-term 215,000 195,000 Other liabilities 10,877 11,468 Total liabilities 831,606 820,270 STOCKHOLDERS' EQUITY Common stock, par value $0.01; 200,000,000 shares authorized; 33,113,379 shares issued and 26,807,818 outstanding at March 31, 2025; 32,989,165 shares issued and 26,737,036 outstanding at December 31, 2024 331 330 Preferred stock, par value $0.01; 50,000,000 shares authorized; 0 shares issued and outstanding at March 31, 2025 and December 31, 2024 — — Treasury stock at par (6,305,561 shares at March 31, 2025; 6,252,129 shares at December 31, 2024) (63 ) (63 ) Additional paid-in capital 137,677 136,872 Retained earnings 650,435 631,541 Accumulated other comprehensive income 5,988 5,970 Total stockholders' equity 794,368 774,650 Total liabilities and stockholders' equity $ 1,625,974 $ 1,594,920 Expand AdvanSix Inc. Condensed Consolidated Statements of Operations (Unaudited) (Dollars in thousands, except share and per share amounts) Three Months Ended March 31, 2025 2024 Sales $ 377,791 $ 336,829 Costs, expenses and other: Costs of goods sold 324,320 333,864 Selling, general and administrative expenses 23,409 23,593 Interest expense, net 1,541 2,699 Other non-operating (income) expense, net (408 ) 90 Total costs, expenses and other 348,862 360,246 Income (loss) before taxes 28,929 (23,417 ) Income tax expense (benefit) 5,585 (6,021 ) Net income (loss) $ 23,344 $ (17,396 ) Earnings per common share Basic $ 0.87 $ (0.65 ) Diluted $ 0.86 $ (0.65 ) Weighted average common shares outstanding Basic 26,838,146 26,878,660 Diluted 27,289,144 26,878,660 Expand AdvanSix Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) (Dollars in thousands) Three Months Ended March 31, 2025 2024 Cash flows from operating activities: Net income (loss) $ 23,344 $ (17,396 ) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 19,178 19,102 (Gain) loss on disposal of assets (210 ) 89 Deferred income taxes 4,054 1,108 Stock-based compensation 1,978 2,211 Amortization of deferred financing fees 155 155 Changes in assets and liabilities, net of business acquisitions: Accounts and other receivables (33,652 ) (5,818 ) Inventories (10,471 ) 20,910 Taxes receivable 448 1,426 Accounts payable 19,362 (52,995 ) Income taxes payable 1,543 (7,098 ) Accrued liabilities (4,949 ) 2,150 Deferred income and customer advances (10,956 ) (4,392 ) Other assets and liabilities 1,619 4,346 Net cash provided by (used for) operating activities 11,443 (36,202 ) Cash flows from investing activities: Expenditures for property, plant and equipment (34,062 ) (35,388 ) Other investing activities (2,732 ) (1,419 ) Net cash used for investing activities (36,794 ) (36,807 ) Cash flows from financing activities: Borrowings from line of credit 118,500 184,500 Repayments of line of credit (98,500 ) (109,500 ) Principal payments of finance leases (247 ) (239 ) Dividend payments (4,290 ) (4,290 ) Purchase of treasury stock (1,486 ) (7,023 ) Issuance of common stock 154 426 Net cash provided by financing activities 14,131 63,874 Net change in cash and cash equivalents (11,220 ) (9,135 ) Cash and cash equivalents at beginning of period 19,564 29,768 Cash and cash equivalents at the end of period $ 8,344 $ 20,633 Supplemental non-cash investing activities: Capital expenditures included in accounts payable $ 14,605 $ 13,442 Expand AdvanSix Inc. Non-GAAP Measures (Dollars in thousands, except share and per share amounts) March 31, 2025 2024 Net cash provided by (used for) operating activities $ 11,443 $ (36,202 ) Expenditures for property, plant and equipment (34,062 ) (35,388 ) Free cash flow (1) $ (22,619 ) $ (71,590 ) (1) Free cash flow is a non-GAAP measure defined as Net cash provided by operating activities less Expenditures for property, plant and equipment. The Company believes that this metric is useful to investors and management as a measure to evaluate our ability to generate cash flow from business operations and the impact that this cash flow has on our liquidity. Expand Reconciliation of Net Income to Adjusted EBITDA and Earnings Per Share to Adjusted Earnings Per Share Three Months Ended March 31, 2025 2024 Net income (loss) $ 23,344 $ (17,396 ) Non-cash stock-based compensation 1,978 2,211 Non-recurring, unusual or extraordinary (income) expense — — Non-cash amortization from acquisitions 532 532 Non-recurring M&A costs — — Income tax benefit relating to reconciling items (430 ) (465 ) Adjusted Net income (loss) (non-GAAP) 25,424 (15,118 ) Interest expense, net 1,541 2,699 Income tax expense (benefit) - Adjusted 6,015 (5,556 ) Depreciation and amortization - Adjusted 18,646 18,570 Adjusted EBITDA (non-GAAP) $ 51,626 $ 595 Sales $ 377,791 $ 336,829 Adjusted EBITDA Margin (non-GAAP) (2) 13.7 % 0.2 % (2) Adjusted EBITDA Margin is defined as Adjusted EBITDA divided by Sales. Expand Three Months Ended March 31, 2025 2024 Net income (loss) $ 23,344 $ (17,396 ) Adjusted Net income (loss) (non-GAAP) 25,424 (15,118 ) Weighted-average number of common shares outstanding - basic 26,838,146 26,878,660 Dilutive effect of equity awards and other stock-based holdings 450,998 — Weighted-average number of common shares outstanding - diluted 27,289,144 26,878,660 EPS - Basic $ 0.87 $ (0.65 ) EPS - Diluted $ 0.86 $ (0.65 ) Adjusted EPS - Basic (non-GAAP) $ 0.95 $ (0.56 ) Adjusted EPS - Diluted (non-GAAP) $ 0.93 $ (0.56 ) The Company believes the non-GAAP financial measures presented in this release provide meaningful supplemental information as they are used by the Company's management to evaluate the Company's operating performance, enhance a reader's understanding of the financial performance of the Company, and facilitate a better comparison among fiscal periods and performance relative to its competitors, as these non-GAAP measures exclude items that are not considered core to the Company's operations. Expand AdvanSix Inc. Appendix (Pre-tax income impact, Dollars in millions) Planned Plant Turnaround Schedule (3) 1Q 2Q 3Q 4Q FY Primary Unit Operation 2017 — ~$10 ~$4 ~$20 ~$34 Sulfuric Acid 2018 ~$2 ~$10 ~$30 — ~$42 Ammonia 2019 — ~$5 ~$5 ~$25 ~$35 Sulfuric Acid 2020 ~$2 ~$7 ~$20 ~$2 ~$31 Ammonia 2021 ~$3 ~$8 — ~$18 ~$29 Sulfuric Acid 2022 ~$1 ~$5 ~$44 (4) — ~$50 Ammonia 2023 ~$2 ~$1 ~$27 — ~$30 Sulfuric Acid 2024 ~$5 ~$3 ~$3 ~$47 (5) ~$58 Ammonia 2025E ~$5 ~$5 — $15-$20 $25-$30 Sulfuric Acid (3) Primarily reflects the impact of fixed cost absorption, maintenance expense, and the purchase of feedstocks which are normally manufactured by the Company. (4) During the multi-site planned plant turnaround, additional required maintenance at our Frankford phenol plant contributed to reduced production across our integrated value chain and a delayed ramp to full operating rates at our Hopewell and Chesterfield sites, resulting in an incremental $15 million unfavorable impact to pre-tax income, which is reflected in this amount and is inclusive of fixed cost absorption, higher maintenance expense and lost sales. (5) During the multi-site planned plant turnaround, additional required maintenance at our Hopewell plant contributed to reduced production across our integrated value chain and a delayed ramp to full operating rates, resulting in an incremental approximately $17 million unfavorable impact to pre-tax income, which is reflected in this amount and is inclusive of fixed cost absorption, higher maintenance expense, and lost sales. Expand
Arab News
02-05-2025
- Business
- Arab News
Pakistan foils bid to smuggle donkey hides worth Rs80 million to China
KARACHI: Pakistan Customs has foiled an attempt to smuggle donkey hides, worth around Rs80 million ($283,862), to China, a customs spokesperson said on Friday. The staff deployed on the Risk Management Profiling System of the Karachi customs collectorate detected a container number SEGU-3154225 cleared from the South Asia Pakistan Port (SAPT) terminal in Karachi, whose export documents showed 285 packages of leather products were being sent to China by Messrs. Wow Trading. The container was allowed to be loaded on a ship after the export collectorate issued a permit, but customs authorities conducted a detailed inspection after being informed by the Anti-Smuggling Organization (ASO) staff and found the prohibited donkey hides in the container. '[The inspection] resulted in the recovery of 14,000 kilograms of prohibited donkey hides, declared under the guise of leather products, in the container, the export of which is prohibited under the export policy of the Government of Pakistan,' Irfan Ali, a customs spokesperson, said in a statement. 'A case has been registered against the exporter under the relevant provisions of the Customs Act. Further investigation is underway.' Pakistan is frequently listed as one of the countries with the highest number of donkey populations worldwide, with Islamabad reporting its donkey population had increased to 5.9 million during the fiscal year 2023-24 from 5.5 million in 2019-2020, according to the Pakistan Economic Survey (PES) 2023-24. The animal's meat and hides are quite popular in China. Gelatin derived from donkey hides is highly sought after in China for its use in Ejiao, a traditional medicinal remedy. Several Chinese eateries sell donkey meat and burgers for consumption. The seizure of donkey hides comes amid a Pakistani government crackdown on smuggling of various goods. 'Karachi Customs Enforcement Collector Moinuddin Wani appreciated and praised the performance of the officers and staff of the enforcement collectorate for this successful operation,' Ali added.
